Ipidacrine Hydrochloride Grindeks (Ipidacrine Hydrochloride)

• Ipidacrine Hydrochloride is an acetylcholinesterase inhibitor used in disorders of cognition and memory.
• Cognitive impairment: improves attention and short‑term memory in patients with mild to moderate deficits.
• Dementia: helps stabilize functional abilities and slows progression of symptoms.
• Alzheimer’s disease: supports cholinergic neurotransmission to mitigate disease‑related cognitive decline.

• Ipidacrine Hydrochloride reversibly binds to the active site of acetylcholinesterase, inhibiting the enzyme’s ability to hydrolyze acetylcholine. This results in increased synaptic concentrations of acetylcholine within the central nervous system, enhancing cholinergic neurotransmission that is typically reduced in cognitive disorders such as dementia and Alzheimer’s disease.

Ipidacrine Hydrochloride may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects

• Nausea: mild to moderate stomach upset.
• Vomiting: occasional emesis after dosing.
• Diarrhea: loose stools, generally self‑limiting.
• Dizziness: transient light‑headedness.
• Headache: mild cranial discomfort.
• Insomnia: difficulty initiating sleep.

Serious or Rare Side Effects

• Bradycardia: significant slowing of heart rate.
• Severe hypotension: marked drop in blood pressure.
• Hepatic dysfunction: elevated liver enzymes.
• Anaphylactic reaction: rare but potentially life‑threatening allergy.
• Seizures: uncommon neurologic events.
• Psychosis: rare emergence of hallucinations or delusions.

• Before initiating therapy with Ipidacrine Hydrochloride, clinicians should consider several safety factors.
• Renal impairment: monitor renal function and adjust therapy as needed.
• Hepatic impairment: use with caution; assess liver enzymes regularly.
• Cardiovascular disease: observe heart rate and blood pressure for bradycardia or hypotension.
• Concomitant anticholinergic drugs: may diminish therapeutic effect.
• Pregnancy: safety not established; avoid unless benefit outweighs risk.
• Store at room temperature: keep in original packaging, protect from moisture and direct sunlight.

Ipidacrine Hydrochloride can interact with other medications that affect cholinergic pathways or metabolism.

Major Interactions (Avoid)

• Other acetylcholinesterase inhibitors: additive cholinergic toxicity.
• Strong anticholinergic agents (e.g., atropine): opposite pharmacologic action.
• Beta‑blockers with bradycardic effect: may exacerbate heart‑rate slowing.

Moderate Interactions (Monitor Closely)

• Cholinergic agonists (e.g., pilocarpine): may increase cholinergic side effects.
• Antihistamines with anticholinergic properties: monitor for reduced efficacy.
• CYP450 inhibitors (if metabolized via CYP pathways): may raise plasma levels.